NCT00886808

Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema

A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of iCo-007 Intravitreal Injection in Subjects With Diffuse Diabetic Macular Edema

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: iCo Therapeutics Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of the study is to evaluate the safety and tolerability of 4 different doses of iCo-007 Intravitreal Injection in patients with diffuse diabetic macular edema.

Conditions

• Diffuse Diabetic Macular Edema

Interventions

Type	Name	Description
DRUG	iCo-007 Intravitreal Injection	single dose iCo-007 Intravitreal Injection

Timeline

• Start date: 2008-02-01
• Primary completion: 2010-05-01
• Completion: 2010-06-01
• First posted: 2009-04-23
• Last updated: 2012-03-22

Locations

4 sites across 1 country: United States